Nath Bio-Genes Corporate Governance Update for FY2026

Company identifiers and listing details

Nath Bio-Genes (India) Limited has reiterated key corporate identifiers in its disclosures, including its BSE and NSE listing references. The company’s BSE scrip code is 537291, while its NSE symbol is NATHBIOGEN. The disclosure also notes the MSEI symbol as NOTLISTED. The company’s ISIN is INE448G01010. These identifiers matter for investors and intermediaries because they ensure accurate tracking across exchanges and depositories. The entity name is stated as NATH BIO-GENES (INDIA) LIMITED.

Financial year and reporting period covered

The document specifies the company’s financial year start date as 01-Apr-2025 and end date as 31-Mar-2026. The reporting quarter is marked as Yearly, with the date of quarter ending stated as 31-Mar-2026. The type of company is listed as Equity. These details align the corporate governance and compliance references with the FY2026 reporting cycle. Investors typically use this information to map governance reporting with annual results and annual report timelines.

SEBI corporate governance applicability noted

The disclosure explicitly states that Annexure I (Part A) of the SEBI Circular dated December 31, 2024 related to the Compliance Report on Corporate Governance is applicable to the entity. This is a factual compliance flag that helps readers interpret why committee composition and meeting records are presented in a structured manner. It also indicates the company is reporting under the applicable corporate governance framework for the period. The disclosure does not provide interpretation beyond applicability, so the key takeaway is the formal confirmation of coverage.

Statutory auditor appointment and tenure

A key governance point in the text is the appointment of M/s Gautam N Associates, Chartered Accountants, as Statutory Auditors. The appointment was made at the company’s Annual General Meeting held on 30th June 2022. The auditors are stated to hold office till the conclusion of the Annual General Meeting to be held in year 2027. This provides a defined tenure window as disclosed by the company. The text does not include the scope of audit beyond the statutory appointment or any fee-related information.

Audit Committee composition as disclosed

The company confirms that the Audit Committee has a Regular Chairperson. It also provides names and roles for committee members, including the chairperson. The disclosed committee members include Madhukar Dhondiraj Deshpande (DIN: 07630081) as Non-Executive - Independent Director and Chairperson, with date of appointment 10-Feb-2021. Vadla Nagbhushanam (DIN: 08863512) is listed as Non-Executive - Independent Director and Member, appointed 10-Feb-2021. Satish Laxminarayan Kagliwal (DIN: 00119601) is listed as Executive Director and Member, appointed 29-Mar-2000. The disclosure does not mention cessations for these members.

Audit Committee meetings and attendance record

The document includes meeting dates and attendance for the Audit Committee. Two meeting dates are explicitly listed: 12-Nov-2025 and 30-Jan-2026. For both meetings, the row indicates 3 directors entitled to attend and 3 directors attended, with 2 independent directors entitled and 2 independent directors attended. The disclosure also marks the meetings as compliant with quorum by indicating Yes. One row includes a duration value of 78 (as presented in the table) for the 30-Jan-2026 meeting. No broader conclusions are provided in the text, but the table format provides a factual snapshot of committee participation.

Board meeting disclosure on quarterly financial results

The company also states that its Board of Directors, at a meeting held on Friday, 11th July 2025, approved Standalone and Consolidated unaudited financial results. The results were for the quarter ended 30th June 2025. The communication references supporting documents including an Annexure-I for financial results and an Annexure-II for the Limited Review Report of the Statutory Auditors. The excerpt does not provide numeric financial figures, profitability, or segment data. It only confirms the approval and the nature of the results as unaudited.

Corporate and investor communication addresses

The disclosure provides a dedicated address for investor correspondence. The correspondence address is Nath Bio-Genes (India) Limited, Nath House, Nath Road, Chhatrapati Sambhaji Nagar (Aurangabad) - 431005, with email investor@nathbiogenes.com and website www.nathbiogenes.com. The contact number provided is 0240-6645555. It also lists exchange addresses for BSE Limited at Phiroze Jeejeebhoy Towers (P.J. Towers), Dalal Street, Mumbai 400001, and NSE at Exchange Plaza, Bandra-Kurla Complex, Bandra (E) with a Mumbai pin code shown in the text. The corporate office is listed as 1, Chateau Windsor, 86, Veer Nariman Road, Churchgate, Mumbai - 400020.

Key facts table from the disclosure

Why these disclosures matter for market participants

For shareholders, governance disclosures like auditor tenure, committee composition, and meeting records are essential reference points, especially during annual reporting cycles. They help market participants understand whether basic governance structures are in place and documented in a consistent manner. The confirmation of the SEBI circular applicability and the audit committee chairperson status are compliance signals that investors often look for while reviewing corporate governance reports. Separately, the board’s approval of unaudited quarterly results for the period ended 30 June 2025 confirms the timing of financial reporting actions, even though this excerpt does not include figures. The next concrete milestone mentioned in the disclosure is the continuation of the statutory auditor’s office until the conclusion of the AGM in 2027.